Oral vaccination with the porcine circovirus type 2 (PCV‐2) capsid protein expressed by Lactococcus lactis induces a specific immune response against PCV‐2 in mice.

Autor: Wang, L., Zhao, D., Sun, B., Yu, M., Wang, Y., Ru, Y., Jiang, Y., Qiao, X., Cui, W., Zhou, H., Li, Y., Xu, Y., Tang, L.
Předmět:
Zdroj: Journal of Applied Microbiology; Jan2020, Vol. 128 Issue 1, p74-87, 14p, 1 Chart, 5 Graphs
Abstrakt: Aims: Porcine circovirus type 2 (PCV2) can cause postweaning, multisystemic wasting syndrome in pigs, which leads to enormous losses in the swine industry worldwide. Here, a genetically engineered Lactococcus strain expressing the main protective antigen of PCV2, the Cap protein, was developed to act against PCV2 infection as an oral vaccine. Methods and Results: Expression of the Cap protein was confirmed via western blot, ELISA and fluorescence microscopy. Over 90% of the recombinant pAMJ399‐Cap/MG1363 survived a simulated gastrointestinal transit. It also survived the murine intestinal tract for at least 11 days. Then, the safety and immunogenicity of pAMJ399‐Cap/MG1363 in orally immunized mice was evaluated. The levels of the sIgA, IgG and cytokines (IL‐4 and IFN‐γ) obtained from the mice immunized with pAMJ399‐Cap/MG1363 were significantly higher than those in the control groups. Conclusions: pAMJ399‐Cap/MG1363 can survive in the gastrointestinal transit and effectively induce mucosal, cellular and humoral immune response against PCV2 infection via oral administration. Significance and Impact of the Study: This study demonstrates the potential of the genetically engineered Lactococcus lactis as a candidate for an oral vaccine against PCV2. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: